GlassScriptPhysician profile
Michael Zimmerman
NPI 1871601302
$11,295.67
in general payments reported to CMS, 2019-2025
37 companies · $2,654 in 2025
The $2,654 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $643 · 2021: $1,233 · 2022: $1,400 · 2023: $2,046 · 2024: $2,301 · 2025: $2,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,885 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.32 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,871.85 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,865.44 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $983.30 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $773.30 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Genzyme Corporation | $735.29 | 2022-2025 | |
| Pfizer INC. | $473.57 | 2019-2025 | |
| Gilead Sciences, INC. | $384.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $350.04 | 2020-2024 | Dificid |
| Braintree Laboratories, INC. | $344.75 | 2019-2025 | Sutab, Suflave |
| Celgene Corporation | $323.87 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $286.37 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $222.78 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $205.87 | 2020-2023 | Linzess |
| Madrigal Pharmaceuticals | $181.76 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $135.86 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $128.59 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $115.53 | 2023-2024 | Dupixent |
| Ardelyx, INC. | $103.89 | 2022-2023 | Ibsrela |
| Orphalan INC | $98.72 | 2024-2025 | Cuvrior |
| Phathom Pharmaceuticals, INC. | $96.08 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $93.29 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $81.24 | 2024-2025 | Omvoh |
| Intra-Sana Laboratories | $56.74 | 2021 | |
| Organon LLC | $46.37 | 2023 | Hadlima, Renflexis |
| Ucb, INC. | $42.20 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $39.77 | 2025 | Iqirvo |
| Medtronic, INC. | $36.14 | 2021-2024 | Gi Genius |
| Capsovision, INC. | $35.86 | 2025 | Capsocam Plus |
| Ethicon US, LLC | $33.95 | 2019-2020 | |
| Novo Nordisk INC | $33.72 | 2025 | Wegovy |
| Celltrion USA INC. | $28.03 | 2025 | Vegzelma |
| Biocon Biologics INC | $21.10 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.59 | 2024 | Cyltezo |
| Alfasigma USA, INC. | $16.44 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.89 | 2023 | |
| Shire North American Group INC | $15.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.